Hemodynamic effect of apelin in a canine model of acute pulmonary thromboembolism.
The peptide apelin is expressed in the pulmonary vasculature and is involved in the pathogenesis of many cardiovascular diseases. It has a biphasic role in the regulation of vasomotor tone related to the vascular endothelium. In this study, we induced acute pulmonary embolism (APE) in dogs with autologous blood clots to assess the effect of apelin on pulmonary and systemic circulation in the acute phase of APE. The expression of apelin mRNA was found to be upregulated in the lung tissue in the early several hours after APE induction and decreased at 24 h. The expression of apelin protein in the pulmonary arteries did not change within 24 h after APE, but significantly increased in the bronchial epithelial cells as early as 1h and decreased at 24 h. In normal anesthetized dogs, intravenous bolus administration of apelin significantly reduced the mean arterial pressure (MAP), but did not significantly affect the mean pulmonary arterial pressure (MPAP). In the dogs with APE, apelin decreased MPAP, whereas its impact on MAP was not significantly different from that in the control group. Taken together, the level of endogenous apelin did not change significantly in the pulmonary arterial wall, whereas its expression in the bronchial epithelium was upregulated in the early stage of APE. The effect of exogenous apelin on vasomotor tone was complicated: it resulted in differential changes in the pulmonary and systemic arterial pressures under different physiological and pathological conditions.
Feng
Jing-Hui
JH
Department of Geratology, First Clinical College of Harbin Medical University, Harbin, Heilongjiang, China.
Li
Wei-Min
WM
Wu
Xiu-Ping
XP
Tan
Xiang-Yang
XY
Gao
Yan-Hui
YH
Han
Chun-Liu
CL
Li
Shu-Qing
SQ
Xie
Hua-Ning
HN
D000818:Animals; D001980:Bronchi / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004285:Dogs; D004848:Epithelium / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D036341:Intercellular Signaling Peptides and Proteins / Q000008:administration & dosage / Q000235:genetics / Q000494:pharmacology / Q000502:physiology*; D008024:Ligands; D008168:Lung / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D008297:Male; D009928:Organ Specificity; D010455:Peptides / Q000235:genetics / Q000502:physiology*; D011652:Pulmonary Circulation / Q000187:drug effects*; D011655:Pulmonary Embolism / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D012333:RNA, Messenger / Q000378:metabolism; D011897:Random Allocation; D043562:Receptors, G-Protein-Coupled / Q000235:genetics / Q000502:physiology*; D013997:Time Factors
D036341:Intercellular Signaling Peptides and Proteins; D008024:Ligands; D010455:Peptides; D012333:RNA, Messenger; D043562:Receptors, G-Protein-Coupled; C495199:apelin-13 peptide